BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 16672127)

  • 1. Early detection of prostate cancer. What do we tell our patients?
    Schröder FH; Erasmus MC
    Can J Urol; 2006 Apr; 13 Suppl 2():37-42. PubMed ID: 16672127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The early detection of prostate cancer. Prostate Cancer Alliance of Canada.
    Can Oncol Nurs J; 1998 Nov; 8(4):262-4. PubMed ID: 9866477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating localized prostate cancer and identifying candidates for focal therapy.
    Sartor AO; Hricak H; Wheeler TM; Coleman J; Penson DF; Carroll PR; Rubin MA; Scardino PT
    Urology; 2008 Dec; 72(6 Suppl):S12-24. PubMed ID: 19095124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening for prostate cancer in U.S. men ACPM position statement on preventive practice.
    Lim LS; Sherin K;
    Am J Prev Med; 2008 Feb; 34(2):164-70. PubMed ID: 18201648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Digital rectal examination in the early detection of prostate cancer.
    Gerber GS; Chodak GW
    Urol Clin North Am; 1990 Nov; 17(4):739-44. PubMed ID: 2219574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer screening: the continuing controversy.
    Wilbur J
    Am Fam Physician; 2008 Dec; 78(12):1377-84. PubMed ID: 19119557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening men for prostate cancer and colorectal cancer: is practice evidence-based?
    Chun FK; Suardi N; Perrotte P; Lebeau T; Guay JP; Benayoun S; Ramirez A; Bénard F; McCormack M; Valiquette L; Karakiewicz P
    Can J Urol; 2007 Dec; 14(6):3727-33. PubMed ID: 18163923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for prostate cancer. Role of ultrasonography.
    Chodak GW
    Urol Clin North Am; 1989 Nov; 16(4):657-61. PubMed ID: 2683297
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline prostate-specific antigen level and risk of prostate cancer and prostate-specific mortality: diagnosis is dependent on the intensity of investigation.
    Connolly D; Black A; Gavin A; Keane PF; Murray LJ
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):271-8. PubMed ID: 18250343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A model of prostate-specific antigen screening outcomes for low- to high-risk men: information to support informed choices.
    Howard K; Barratt A; Mann GJ; Patel MI
    Arch Intern Med; 2009 Sep; 169(17):1603-10. PubMed ID: 19786680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of clinically occult prostate cancer.
    Morse RM; Resnick MI
    Urol Clin North Am; 1990 Aug; 17(3):567-74. PubMed ID: 2197767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Searching for suppressor genes in prostate cancer.
    Peehl DM
    Cancer Surv; 1991; 11():25-34. PubMed ID: 1668728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening for prostate cancer (PC)--an update on recent findings of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Urol Oncol; 2008; 26(5):533-41. PubMed ID: 18774469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conventional treatments of localized prostate cancer.
    Zerbib M; Zelefsky MJ; Higano CS; Carroll PR
    Urology; 2008 Dec; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate-specific antigen kinetics in localized and advanced prostate cancer.
    Fitzpatrick JM; Banu E; Oudard S
    BJU Int; 2009 Mar; 103(5):578-87. PubMed ID: 19210674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate cancer early detection clinical practice guidelines in oncology.
    Babaian RJ; Partin AW;
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S42-55. PubMed ID: 19795575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.